Skip to content
10-Q

Quarterly Report

Marker Therapeutics, Inc. MRKR

0001410578-25-001342

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 11.31M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $13.69M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $19.19M
Current Liabilities Q1 2025 · Mar 31, 2025 $2.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $3.46M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.46M
Current Assets Q1 2025 · Mar 31, 2025 $16.99M
Current Assets Q1 2025 · Dec 31, 2024 $22.02M
Total Assets Q1 2025 · Mar 31, 2025 $16.99M
Total Assets Q1 2025 · Dec 31, 2024 $22.02M
Shares Diluted Q1 2025 · Mar 31, 2024 8.9M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.84M
Stockholders Equity Q1 2025 · Mar 31, 2024 $11.79M
Stockholders Equity Q1 2025 · Dec 31, 2023 $14.05M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.27
Eps Basic Q1 2025 · Mar 31, 2024 −$0.27
Sga Expense Q1 2025 · Mar 31, 2024 $1.22M
Rd Expense Q1 2025 · Mar 31, 2024 $2.58M
Net Income Q1 2025 · Mar 31, 2024 −$2.39M
Operating Income Q1 2025 · Mar 31, 2024 −$2.55M